Ikarian Capital, LLC Cassava Sciences Inc Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $224,077 - $725,478	-5,362 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $172,388 - $481,078	5,362 New	5,362 $458,000
Q2 2020 Aug 14, 2020	SELL	$2.04 - $9.64 $612,000 - $2.89 Million	-300,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.26 - $9.65 $977,999 - $2.9 Million	300,000 New	300,000 $1.23 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $93.8M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.